These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34050731)

  • 1. Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.
    Marot S; Malet I; Leducq V; Abdi B; Teyssou E; Soulie C; Wirden M; Rodriguez C; Fourati S; Pawlotsky JM; Boutolleau D; Burrel S; Calvez V; Marcelin AG; Jary A
    Clin Infect Dis; 2022 Mar; 74(4):707-710. PubMed ID: 34050731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
    J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals.
    Luczkowiak J; Labiod N; Rivas G; Rolo M; Lasala F; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Infect Dis; 2022 Jun; 225(11):1905-1908. PubMed ID: 34963008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.
    Saade C; Gonzalez C; Bal A; Valette M; Saker K; Lina B; Josset L; Trabaud MA; Thiery G; Botelho-Nevers E; Paul S; Verhoeven P; Bourlet T; Pillet S; Morfin F; Trouillet-Assant S; Pozzetto B; On Behalf Of Covid-Ser Study Group
    Emerg Microbes Infect; 2021 Dec; 10(1):1499-1502. PubMed ID: 34176436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2.
    Gidari A; Schiaroli E; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Francisci D
    J Infect; 2022 Nov; 85(5):e125-e126. PubMed ID: 36031155
    [No Abstract]   [Full Text] [Related]  

  • 8. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose.
    Vicenti I; Basso M; Gatti F; Scaggiante R; Boccuto A; Zago D; Modolo E; Dragoni F; Parisi SG; Zazzi M
    Int J Infect Dis; 2021 Nov; 112():40-44. PubMed ID: 34481967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
    Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
    J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
    Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
    BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
    Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers.
    Laing ED; Weiss CD; Samuels EC; Coggins SA; Wang W; Wang R; Vassell R; Sterling SL; Tso MS; Conner T; Goguet E; Moser M; Jackson-Thompson BM; Illinik L; Davies J; Ortega O; Parmelee E; Hollis-Perry M; Maiolatesi SE; Wang G; Ramsey KF; Reyes AE; Alcorta Y; Wong MA; Lindrose AR; Duplessis CA; Tribble DR; Malloy AMW; Burgess TH; Pollett SD; Olsen CH; Broder CC; Mitre E
    Emerg Infect Dis; 2022 Apr; 28(4):828-832. PubMed ID: 35203111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
    Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M
    Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2.
    Watanabe Y; Matsuba I; Watanabe K; Kunishima T; Takechi Y; Takuma T; Araki Y; Hirotsu N; Sakai H; Oikawa R; Danno H; Fukuda M; Futagami S; Wada K; Yamamoto H; Itoh F; Oda I; Hatori Y; Degawa H
    J Clin Lab Anal; 2022 Jul; 36(7):e24545. PubMed ID: 35678628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
    Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
    Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
    Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
    Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.